Anzeige
Mehr »
Login
Sonntag, 10.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Breaking News: Das geheime Potenzial von 55?$ pro Aktie in einem Clean-Energy-Deal!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWHD | ISIN: US88583P1049 | Ticker-Symbol: 8LL
Frankfurt
08.11.24
15:29 Uhr
1,330 Euro
-0,020
-1,48 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
374WATER INC Chart 1 Jahr
5-Tage-Chart
374WATER INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3301,71019:02
ACCESSWIRE
451 Leser
Artikel bewerten:
(2)

374Water Inc.: 374Water Releases First Quarter 2024 Results and Provides Business Update

Finanznachrichten News

New CEO Chris Gannon unveils Product Development, Commercialization and Go-to-Market Objectives

DURHAM, NC / ACCESSWIRE / May 15, 2024 / 374Water Inc. (NASDAQ:SCWO), a global leader in cutting-edge, sustainable waste management technologies, today provides a business update and reports its financial results for the first quarter ended March 31, 2024.

"In just under a month, we have hit the ground running developing a strategic plan to unlock the value inherent in this enterprise. I have immersed myself in our technology and our market opportunities to chart the best path forward in our product development, commercialization, and go-to-market approach," said Chris Gannon, CEO of 374Water. "We have a massive opportunity in front of us to take advantage of regulatory tailwinds driving demand for technologies like our AirSCWO system. Over the ensuing months, we will provide more detail and clarity on our go forward strategy, with a focus on four key areas: (1) executing on our municipal biosolid/sludge and federal/DOD contractual obligations which is an important proof point; (2) expanding the application of our AirSCWO systems to industrial and other waste streams; (3) securing new manufacturing and engineering facilities; and (4) expanding our compliment of talented engineers and field personnel, as well as our leadership team."

Financial Highlights

  • For the three-month period ended March 31, 2024, the Company generated revenue of $315,000 which compares to $801,000 for the three months ending March 31, 2023, a 61% decrease. Our revenue is primarily based on progress toward completion of our sold unit and also includes the sale of treatability services. Costs associated with our sold unit have started to decline as we reach the end of our fabrication and testing, which have had a direct correlation to the reduced revenue recognized this year. This has had a direct impact on our change in revenue year-over-year.
  • Total Operating Expenses for the quarter ended March 31, 2024, increased marginally to $1.9 million from $1.8 million in the prior year quarter driven primarily by an increase in R&D expense.

Capital Structure

  • As of March 31, 2024, the Company had working capital of $11.7 million. We are actively working on optimizing our operational efficiencies and exploring new market opportunities, all aimed at long-term value creation while remaining steadfast in our commitment to innovation and excellence. A primary financial goal for the Company is to extend its runway while scaling the business.

Business Highlights

  • On April 23, 2024 the Company announced the appointment of Chris Gannon as its new President and Chief Executive Officer. Mr. Gannon brings deep executive leadership experience in multiple disciplines and industries, including environmental technology development, highly engineered product, advanced manufacturing, and global customer support and service with customers in the municipal, industrial, commercial, defense, and medical spaces.
  • In March 2024, the Company announced a new contract with the City of Orlando, highlighted by the deployment of an AirSCWO 6 service unit, which will be integrated into Orlando's Iron Bridge Water Pollution Control Facility. This AirSCWO 6 unit is expected to deploy in 2024.
  • 374Water continued its progress on an expected 2024 deployment to Orange County Sanitation District. The Company is underway with factory acceptance testing and once achieved, will begin mobilizing the unit to Orange County.
  • The Company continues to focus on executing demonstrations and securing demonstration partners within the municipal biosolids, federal and military PFAS, and industrial markets.
  • The Company is in active discussions with major TSDF operators to not only serve as technology development and commercialization partners, focused initially on PFAS intensive waste streams, but also serve as long-term waste destruction partners. The Company places a priority these partnerships as we continue to scale our commercial grade technology to meet growing demand for AirSCWO technology.

Earnings Conference Call

Management will hold a conference call at 10:00 am Pacific Time (1:00 pm Eastern Time) on Friday, May 17, 2024, to provide a more detailed business update and discussion of quarterly results. Participants who wish to join the conference by telephone can access the call by dialing (Toll Free) 888-506-0062 or (International) 973-528-0011. Participants may join the live webcast by accessing it at the webcast registration link here: https://www.webcaster4.com/Webcast/Page/3040/50613.

A webcast replay will be available through May 31, 2024 on the Investors Section of the Company's website at https://374water.com/investor-relations/.

For more on AirSCWO or about our team, visit 374Water.com or follow us on LinkedIn.

About 374Water

374Water Inc. (NASDAQ:SCWO) is a global cleantech company with innovative solutions to wastewater treatment and waste management issues. 374Water's AirSCWO technology transforms organic "wastes" into minimal impact, value-added products, effectively shifting the waste management paradigm from disposal to resource recovery. 374Water is leading a new era of creating value in sustainability, eliminating PFAS and protecting our communities. Follow us on LinkedIn.

Cautionary Language

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning.

Investor Contact:
Heather Crowell
ir@374water.com

Media Contact:
Christian Rizzo
media@374water.com

374Water Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
March 31, 2024 (Unaudited) and December 31, 2023


March 31,
2024
December 31,
2023
Assets


Current Assets:


Cash
$7,936,161 $10,445,404
Accounts receivable, net of allowance
84,324 64,792
Unbilled accounts receivable
1,771,609 1,494,553
Other accounts receivable
34,161 39,749
Inventory, net
2,601,658 2,276,677
Prepaid expenses
921,365 581,085
Total Current Assets
13,349,278 14,902,260
Long-Term Assets:
Property, and Equipment, net
223,339 230,971
Intangible asset, net
971,691 988,029
Total Long-Term Assets
1,195,030 1,219,000
Total Assets
$14,544,308 $16,121,260
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable and accrued expenses
$755,721 $572,297
Accrued contract loss provision
600,000 500,000
Accrued legal settlement
135,000 135,000
Unearned revenue
132,768 130,000
Other liabilities
10,408 36,787
Total Current Liabilities
1,633,897 1,374,084
Total Liabilities
1,633,897 1,374,084
Commitments and contingencies (Note 9)
Stockholders' Equity
Preferred stock: 50,000,000 convertible Series D preferred shares authorized; par value $0.0001 per share, nil issued and
outstanding at March 31, 2024 and December 31, 2023
- -
Common stock: 200,000,000 common shares authorized, par value $0.0001 per share, 132,670,446 and 132,667,107 shares
outstanding at March 31, 2024 and December 31, 2023, respectively
13,266 13,266
Additional paid-in capital
30,872,643 30,684,943
Accumulated deficit
(17,977,969) (15,953,504)
Accumulated other comprehensive loss
2,471 2,471
Total Stockholders' Equity
12,910,411 14,747,176
Total Liabilities and Stockholders' Equity
$14,544,308 $16,121,260

374Water, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
For the three months ended March 31, 2024 and 2023 (Unaudited)


2024 2023
Revenue
$315,278 $801,458
Cost of goods sold
617,298 720,146
Gross margin
(302,020) 81,312
Operating Expenses
Research and development
535,147 355,905
Compensation and related expenses
651,604 718,760
Professional fees
252,705 99,572
General and administrative
459,727 585,659
Total Operating Expenses
1,899,183 1,759,896

Loss from Operations
(2,201,203) (1,678,584)

Other Income
Interest income
104,620 37,859
Other income
72,118 382
Total Other Income
176,738 38,241
Net Loss before Income Taxes
(2,024,465) (1,640,343)
Provision for Income Taxes
- -

Net Loss
$(2,024,465) $(1,640,343)

Other comprehensive income
Foreign currency translation gain
- 824
Unrealized gain on marketable securities
- 18,967
Total other comprehensive loss
- 19,791
Total comprehensive loss
(2,024,465) (1,620,552)
Net Loss per Share - Basic and Diluted
$(0.02) $(0.01)

Weighted Average Common Shares Outstanding - Basic and Diluted
132,668,777 127,146,695

374Water Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
For the three months ended March 31, 2024 and 2023 (Unaudited)

Cash Flows from Operating Activities
2024 2023
Net loss
$(2,024,465) $(1,640,343)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
24,560 29,105
Issuance of common stock for services
4,500 -
Stock-based compensation
183,200 214,924
Gain on foreign currency translation
- 824
Increase in inventory reserve
50,000 -
Changes in operating assets and liabilities:
Accounts receivable
(19,532) (26,188)
Unbilled accounts receivable
(277,056) (754,290)
Other receivables
5,588 (308,374)
Inventory
(374,981) (127,309)
Prepaid expenses
(340,280) 23,285
Accounts payable and accrued expenses
183,424 (581,582)
Accrued contract loss provision
100,000 -
Unearned revenue
2,768 5,000
Other liabilities
(26,379) (13,528)
Net Cash Used In Operating Activities
(2,508,653) (3,178,176)

Cash Flows from Investing Activities
Purchase of equipment
- (7,303)
Increase in intangible assets
(590) (2,705)

Cash Used In Investing Activities
(590) (10,008)

Cash Flowfrom Financing Activities
Proceeds from the sale of common stock
- 8,294,708
Cash Provided by Financing Activities
- 8,294,708

Net (Decrease) Increase in Cash
(2,509,243) 5,106,224
Cash, Beginning of the Period
10,445,404 4,046,937
Cash, End of the Period
$7,936,161 $9,153,161

SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest
$- $-
Cash paid for taxes
$- $-

SOURCE: 374Water Inc.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.